Scott Solomon, MD
Cardiovascular Disease · Boston, MANPI 1528025996
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $432,278 of the $498,222 with a category attached, or 86.8%. It is spread thinly across 26 manufacturers, the largest accounting for just 22.1%. Among cardiovascular disease clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 276 payments — averaging $1805.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis Pharma AG$110K
- AstraZeneca$91K
- Bayer$81K
- GSK$54K
- Astrazeneca UK Limited$42K
- E.r. Squibb & Sons, L.L.C.$25K
- plus $95K from 20 others
Across 95 payments — averaging $165,168 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$5.7M
- AstraZeneca$3.6M
- Astrazeneca UK Limited$1.3M
- Ionis Pharmaceuticals, Inc.$1.2M
- Sanofi Pasteur Inc.$854K
- Amgen$711K
- plus $2.3M from 11 others
What the payments were for
- Consulting fees$432,27887%
- Speaking & faculty fees$5,8031%
- Travel & lodging$53,28611%
- Food & beverage$6,8551%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis Pharma AG | 50 | $110,068 |
| AstraZeneca(2 entities) | 43 | $90,570 |
| Bayer | 18 | $81,353 |
| GSK | 28 | $53,771 |
| Astrazeneca UK Limited | 42 | $42,036 |
| E.r. Squibb & Sons, L.L.C. | 13 | $25,275 |
| Alnylam Pharmaceuticals Inc. | 9 | $14,137 |
| Boston Scientific | 5 | $11,706 |
| Sanofi Pasteur Inc. | 10 | $11,260 |
| American Regent | 2 | $10,836 |
| Astrazeneca AB | 10 | $9,888 |
| Novo Nordisk AS | 7 | $9,224 |
| Roche Diagnostics International Ltd | 3 | $6,384 |
| Novartis | 17 | $5,290 |
| Roche Diagnostics Corporation | 8 | $4,301 |
| Actelion Pharmaceuticals, Ltd | 1 | $3,535 |
| Amgen | 1 | $3,016 |
| Eli Lilly | 1 | $2,400 |
| Boehringer Ingelheim International GmbH | 1 | $1,300 |
| Sarepta Therapeutics, Inc. | 1 | $1,080 |
| Daiichi Sankyo Inc. | 1 | $577 |
| Sandoz | 1 | $125 |
| Modernatx, Inc. | 1 | $46 |
| Agepha Pharma FZ LLC | 1 | $16 |
| Seagen Inc. | 1 | $15 |
| Strongbridge US Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LCZ696B_ENTRESTO_CARDIOVASCULAR$58,054
- LCZ696D_ENTRESTO_CARDIOVASCULAR$26,713
- ENTRESTO$23,965
- FARXIGA$11,654
- ILARIS$11,484
- FLUZONE HIGH-DOSE$10,992
- INJECTAFER$10,836
- CLINICAL TRIAL PRODUCT$10,000
- Kerendia$7,016
- ENTRESTO_ENTRESTO_CARDIOVASCULAR$5,148
- CD cobas Reagents$3,845
- AMVUTTRA$2,820
- RDI Research$2,429
- ONPATTRO$2,115
- WAINUA$1,611
- JARDIANCE$1,300
- POC cobas Accutrend Meters, Strips and Assessories$348
- LCZ696G_ENTRESTO_CARDIOVASCULAR$135
How this compares
$498,222 in reported general payments places this provider in the 95th percentile of 750 cardiovascular disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 53 | $39,461 |
| EliquisApixaban | 24 | $39,390 |
| EntrestoSacubitril/Valsartan | 40 | $35,990 |
| JardianceEmpagliflozin | 19 | $25,060 |
| Metoprolol Succinate | 56 | $882 |
| Atorvastatin Calcium | 40 | $387 |
| Rosuvastatin Calcium | 16 | $315 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 11 | $229 |
| ClopidogrelClopidogrel Bisulfate | 12 | $173 |
| Furosemide | 15 | $150 |
| Amlodipine Besylate | 23 | $128 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $90,570 | $39,46153 claims |
| NovartisEntresto | $5,290 | $35,99040 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 750 cardiovascular disease providers in Massachusetts.
Other cardiovascular disease in Boston
- Marc SabatineBoston$3.9M
- Elizabeth NabelBoston$2.2M
- Kenneth RosenfieldBoston$1.4M
- James JanuzziBoston$1.1M
- Muthiah VaduganathanBoston$972K
- Joseph LoscalzoBoston$926K
- Sunil KapurBoston$823K
- Paul ZeiBoston$786K
- Paul RidkerBoston$572K
- Ignacio Inglessis-AzuajeBoston$545K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.